Collective Audience (CAUD) Competitors $0.04 0.00 (0.00%) As of 08/1/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock CAUD vs. ISPC, WAI, MRIN, DKDCA, RVYL, LICN, AUUD, TC, APDN, and VCIGShould you be buying Collective Audience stock or one of its competitors? The main competitors of Collective Audience include iSpecimen (ISPC), Top KingWin (WAI), Marin Software (MRIN), Data Knights Acquisition (DKDCA), Ryvyl (RVYL), Lichen International (LICN), Auddia (AUUD), Token Cat (TC), Applied DNA Sciences (APDN), and VCI Global (VCIG). These companies are all part of the "business services" industry. Collective Audience vs. Its Competitors iSpecimen Top KingWin Marin Software Data Knights Acquisition Ryvyl Lichen International Auddia Token Cat Applied DNA Sciences VCI Global Collective Audience (NASDAQ:CAUD) and iSpecimen (NASDAQ:ISPC) are both small-cap business services companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability. Which has more risk and volatility, CAUD or ISPC? Collective Audience has a beta of 2.93, suggesting that its stock price is 193% more volatile than the S&P 500. Comparatively, iSpecimen has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500. Is CAUD or ISPC more profitable? Collective Audience has a net margin of 0.00% compared to iSpecimen's net margin of -139.63%. Collective Audience's return on equity of 0.00% beat iSpecimen's return on equity.Company Net Margins Return on Equity Return on Assets Collective AudienceN/A N/A N/A iSpecimen -139.63%-285.20%-114.37% Which has preferable earnings and valuation, CAUD or ISPC? Collective Audience has higher revenue and earnings than iSpecimen. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCollective Audience$12.14M0.07-$4.57MN/AN/AiSpecimen$8.06M0.46-$12.50M-$12.89-0.11 Do institutionals & insiders have more ownership in CAUD or ISPC? 60.8% of Collective Audience shares are owned by institutional investors. Comparatively, 13.6% of iSpecimen shares are owned by institutional investors. 58.0% of Collective Audience shares are owned by company insiders. Comparatively, 12.2% of iSpecimen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media refer more to CAUD or ISPC? In the previous week, iSpecimen had 5 more articles in the media than Collective Audience. MarketBeat recorded 5 mentions for iSpecimen and 0 mentions for Collective Audience. iSpecimen's average media sentiment score of 0.40 beat Collective Audience's score of 0.00 indicating that iSpecimen is being referred to more favorably in the news media. Company Overall Sentiment Collective Audience Neutral iSpecimen Neutral SummaryCollective Audience beats iSpecimen on 8 of the 11 factors compared between the two stocks. Get Collective Audience News Delivered to You Automatically Sign up to receive the latest news and ratings for CAUD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CAUD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CAUD vs. The Competition Export to ExcelMetricCollective AudienceManagement consulting services IndustryComputer SectorNASDAQ ExchangeMarket Cap$896K$18.42M$29.20B$9.51BDividend YieldN/AN/A3.08%4.09%P/E RatioN/A6.8648.0923.80Price / Sales0.0767.701,544.9766.58Price / CashN/A25.4038.0757.96Price / BookN/A0.567.415.55Net Income-$4.57M-$13.46M$782.10M$259.03M7 Day PerformanceN/A-0.87%-3.65%-4.59%1 Month PerformanceN/A7.06%-0.11%4.46%1 Year PerformanceN/A3.12%52,642.35%18.03% Collective Audience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CAUDCollective AudienceN/A$0.04flatN/A-91.6%$896K$12.14M0.0023ISPCiSpecimen0.805 of 5 stars$1.24-3.9%N/A+458.9%$3.22M$9.29M-0.1060News CoverageUpcoming EarningsGap DownHigh Trading VolumeWAITop KingWinN/A$0.37-7.1%N/AN/A$2.92M$3.75M0.00N/APositive NewsGap DownMRINMarin SoftwareN/A$0.90flatN/AN/A$2.87M$17.73M-0.23180DKDCAData Knights AcquisitionN/A$0.48-2.9%N/A-65.7%$2.50MN/A-2.542Gap DownRVYLRyvyl0.7118 of 5 stars$0.26-10.1%N/A-86.4%$2.45M$56M-0.0350Positive NewsShort Interest ↑LICNLichen InternationalN/A$3.93-3.2%N/A-99.2%$2.43M$41.48M0.00390Positive NewsAUUDAuddia0.1903 of 5 stars$4.18-8.1%N/A-78.3%$2.32MN/A-0.1020Positive NewsUpcoming EarningsGap DownTCToken CatN/A$0.68+0.1%N/A-62.2%$2.16M$6.74M0.00620News CoverageGap UpAPDNApplied DNA Sciences0.1374 of 5 stars$4.63-3.9%N/A-98.4%$2.10M$3.43M-0.0170Upcoming EarningsShort Interest ↑VCIGVCI Global1.1087 of 5 stars$0.94-6.0%N/A-99.7%$2.10M$27.83M0.00102 Related Companies and Tools Related Companies iSpecimen Competitors Top KingWin Competitors Marin Software Competitors Data Knights Acquisition Competitors Ryvyl Competitors Lichen International Competitors Auddia Competitors Token Cat Competitors Applied DNA Sciences Competitors VCI Global Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CAUD) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Collective Audience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Collective Audience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CAUD Stock Alerts